Market news

4D Molecular Therapeutics (FDMT) has enrolled the first patients in a phase 3 trial of 4D-150 in dia

4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2

David Kirn, Director, President and Chief Executive Officer, on September 14, 2026, sold 58,333 shar

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28, accordin

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference: Wednesday, September

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Dogwood Therapeutics Inc (DWTX-Q) from The Globe and Mail including charting and trades.

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 11, 2026, the compensation committee of the Company’s board of directors granted five new non-executive employees 35,200 Restricted Stock Units (RSUs). The RSUs

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS, highlighting long-term continuous treatment effect and ongoing favorable safety profilePlan to initiate a 4D-150 DME Phase 3 in Q3 2026Company to host an Investor Day on October 21, 2026, in New York CityEntered into a strategic credit facility agreement with Hercules Capital, Inc. for

4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28.67, accor

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction...

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs wer